Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration

Eyconis INC.

Summary

This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

Eligibility

Age range: 50+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria * Willing and able to comply with clinic visits and study-related procedures * Provide signed informed consent Exclusion Criteria: * Known hypersensitivity or known allergy that would preclude study drug administration * Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access * Uncontrolled diabetes mellitus * History of cerebrovascular accident (CVA) or myocardial infarc…

Interventions

Biological
EYC-0305

Summary

Eligibility

Interventions

Locations (6)